Apyx Medical Posts Encouraging Data From Renuvion Device In Sagging Skin

Apyx Medical Corp  (NASDAQ: APYX ) announced results  from Phase 2 of its Investigational Device Exemption (IDE) study of the Renuvion device to improve the appearance of lax skin in the neck and submental region. The 65-subject study showed that the primary effectiveness ... Full story available on Benzinga.com